The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will hold a joint meeting Wednesday to consider an application by Specgx LLC, a business unit of Mallinckrodt plc, of Staines-Upon-Thames, U.K., for an abuse-deterrent, immediate-release tablet formulation of oxycodone. If approved, MNK-812 would be only the second immediate-release opioid to get abuse-deterrent labeling in the U.S.